Since 1990, Dr. Royston is a founding Managing Partner of Forward Ventures in San Diego, from 1990-2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was on the oncology faculty of UC, San Diego. In addition to Hybritech, he was a co-founder of IDEC Corporation in 1986, which merged with Biogen to form BiogenIdec. Dr. Royston has been instrumental in the formation, financing and development of numerous biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Corixa (acquired by GlaxoSmithKline); Dynavax; Morphotek (acquired by Eisai), Sequana Therapeutics (acquired by Celera); TargeGen (acquired by Sanofi –Aventis), and Triangle Pharmaceuticals (acquired by Gilead). Dr. Royston’s recent portfolio investments include HemaQuest, LigoCyte (Chairman), and Syndax. Dr. Royston received his B.A. (1967) and M.D. (1970) degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board.